General Toxicity Notes
Avoid all oral hypoglycemic agents on CRRT.
Half-Life (Normalesrd) Hours
8-11/No data
Plasma Protein Binding %
85-95
Volume Of Distribution L/Kg
0.24
Dose For Normal Renal Function
80-320 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
50-100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
Avoid [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Avoid [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No data
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable
References
Holmes B, Heel RC, Brogden RN, Speight TM, Avery GS. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs. 1984; 27: 301-27. [PMID: 6373223] / Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs. 1993; 46: 92-125. [PMID: 7691511]